A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer, Metastasis

In brief

This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.

Key facts

Study ID

NCT00371254

Run by

Bristol-Myers Squibb

People needed

55

Starts

2006-12-01

Expected to finish

2008-09-01

Last updated by the study team

2011-03-15

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• females, 18 or older
• recurrent or progressive locally advanced, or 'triple negative' metastatic breast cancer
• paraffin-embedded tissue block must be available
• measurable disease
• prior chemotherapy with an anthracycline, a taxane, or both (neoadjuvant, adjuvant, or metastatic setting)
• 0, 1 or 2 chemotherapies in the metastatic setting
• adequate organ function

You may not qualify if…

• Metastatic disease confined to bone only
• Symptomatic CNS metastasis
• Concurrent medical condition which may increase the risk of toxicity
• Unable to take oral medication

Where it is running

• Ucsf-Comprehensive Cancer Center — San Francisco, California, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• Dana-Farber Cancer Inst — Boston, Massachusetts, United States
• Montefiore Medical Center — The Bronx, New York, United States
• University Of Texas Md Anderson Cancer Ctr — Houston, Texas, United States
• Local Institution — Paris, France
• Local Institution — Toulouse, France
• Local Institution — Modena, Italy
• Local Institution — Barcelona, Spain
• Local Institution — Lleida, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.